AFT Pharmaceuticals’ shares fall as drug fails FDA threshold

AFT Pharmaceuticals’ shares fall as drug fails FDA threshold
AFT Pharmaceuticals managing director Hartley Atkinson still believes Pascomer shows promise. (Image: AFT Pharmaceuticals)
Riley Kennedy
AFT Pharmaceuticals’ shares have fallen this morning after the company said a drug it is developing to treat facial angiofibromas (FA) had failed to reach the threshold for US Food and Drug Administration (FDA) registration.The company’s shares declined 3.3% to $3.80 in morning trading, after the pharmaceutical company released the findings of its study of its orphan drug Pascomer, which it said found “statistically significant” benefits. However, it did not reach the threshold on the IGA scale – a five-point...

More Markets

NZ sharemarket steady despite US slump
Markets Market Close

NZ sharemarket steady despite US slump

Financial adviser says investors holding their breath for reporting season.

ASB's $35.5m mystery payout to customers
Markets

ASB's $35.5m mystery payout to customers

CBA reveals A$33m remediation provision for ASB customers ahead of A$10b expected result.

Strong lead from US carries NZX 50 up 1.5%
Markets Market Close

Strong lead from US carries NZX 50 up 1.5%

"Bad news is good news," one analyst said.

Gregor Thompson 05 Aug 2025